In collaboration with our partner CPI (UK), we have successfully developed non-toxic ambient temperature liquid-stable mRNA-LNP formulations that significantly improve stability, potency, and pharmacokinetics.

Using our pioneering TheraPHIX™ stabilization technology, we demonstrated that after 3 months of storage at 37°C in an external DES, mRNA retains 48% of its integrity, compared to complete degradation (0%) in a standard buffer solution.

This extends the shelf-life of mRNA vaccines and therapeutics, reduces transportation costs and energy consumption, and enhances broader distribution and accessibility, preparing us to better tackle future health challenges.